These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38117531)

  • 21. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
    Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
    Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
    Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
    Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1.
    Polier G; Ding J; Konkimalla BV; Eick D; Ribeiro N; Köhler R; Giaisi M; Efferth T; Desaubry L; Krammer PH; Li-Weber M
    Cell Death Dis; 2011 Jul; 2(7):e182. PubMed ID: 21776020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
    Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
    Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies.
    Alcon C; Manzano-Muñoz A; Montero J
    Clin Cancer Res; 2020 Feb; 26(4):761-763. PubMed ID: 31843752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
    Thomas D; Powell JA; Vergez F; Segal DH; Nguyen NY; Baker A; Teh TC; Barry EF; Sarry JE; Lee EM; Nero TL; Jabbour AM; Pomilio G; Green BD; Manenti S; Glaser SP; Parker MW; Lopez AF; Ekert PG; Lock RB; Huang DC; Nilsson SK; Récher C; Wei AH; Guthridge MA
    Blood; 2013 Aug; 122(5):738-48. PubMed ID: 23775716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
    Gerlach D; Tontsch-Grunt U; Baum A; Popow J; Scharn D; Hofmann MH; Engelhardt H; Kaya O; Beck J; Schweifer N; Gerstberger T; Zuber J; Savarese F; Kraut N
    Oncogene; 2018 May; 37(20):2687-2701. PubMed ID: 29491412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer.
    Zhang H; Huang C; Gordon J; Yu S; Morton G; Childers W; Abou-Gharbia M; Zhang Y; Jelinek J; Issa JJ
    Clin Epigenetics; 2024 Jan; 16(1):3. PubMed ID: 38172923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CDK9 inhibitors in multiple myeloma: a review of progress and perspectives.
    Borowczak J; Szczerbowski K; Ahmadi N; Szylberg Ł
    Med Oncol; 2022 Jan; 39(4):39. PubMed ID: 35092513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
    Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
    Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ligand- and structure-based identification of novel CDK9 inhibitors for the potential treatment of leukemia.
    Zhang H; Huang J; Chen R; Cai H; Chen Y; He S; Xu J; Zhang J; Wang L
    Bioorg Med Chem; 2022 Oct; 72():116994. PubMed ID: 36087428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers.
    Freeman DB; Hopkins TD; Mikochik PJ; Vacca JP; Gao H; Naylor-Olsen A; Rudra S; Li H; Pop MS; Villagomez RA; Lee C; Li H; Zhou M; Saffran DC; Rioux N; Hood TR; Day MAL; McKeown MR; Lin CY; Bischofberger N; Trotter BW
    J Med Chem; 2023 Dec; 66(23):15629-15647. PubMed ID: 37967851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.
    Han X; Song N; Saidahmatov A; Wang P; Wang Y; Hu X; Kan W; Zhu W; Gao L; Zeng M; Wang Y; Li C; Li J; Liu H; Zhou Y; Wang J
    J Med Chem; 2021 Oct; 64(19):14647-14663. PubMed ID: 34477384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors.
    Xu Z; Zhang B; Liu Z; Gou S
    Eur J Med Chem; 2022 Dec; 244():114875. PubMed ID: 36332552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
    Wei D; Wang H; Zeng Q; Wang W; Hao B; Feng X; Wang P; Song N; Kan W; Huang G; Zhou X; Tan M; Zhou Y; Huang R; Li J; Chen XH
    J Med Chem; 2021 Oct; 64(19):14822-14847. PubMed ID: 34538051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDK9 Inhibitor Induces Apoptosis, Autophagy, and Suppression of Tumor Growth in Adult T-Cell Leukemia/Lymphoma.
    Kato N; Kozako T; Ohsugi T; Uchida Y; Yoshimitsu M; Ishitsuka K; Aikawa A; Honda SI
    Biol Pharm Bull; 2023; 46(9):1269-1276. PubMed ID: 37661406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma.
    Walker RL; Hornicek FJ; Duan Z
    Biochem Pharmacol; 2024 Aug; 226():116342. PubMed ID: 38848777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
    Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
    Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDK9: Therapeutic Perspective in HCC Therapy.
    Borowczak J; Szczerbowski K; Stec E; Grzanka D; Szylberg Ł
    Curr Cancer Drug Targets; 2020; 20(5):318-324. PubMed ID: 32048975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.